
Release date: 2026-01-15 16:36:59 Article From: Lucius Laos Recommended: 204
Pralsetinib is indicated for the treatment of patients with advanced or metastatic (spread) medullary thyroid carcinoma (MTC) whose tumors harbor abnormal RET genes (RET-mutant type).
Currently, Pralsetinib manufactured by Lucius Pharmaceuticals is available in only one specification: each capsule contains 100 mg, with 120 capsules per box. This specification is suitable for a full treatment cycle, facilitating patients to take the medication continuously as prescribed by physicians. The specific price of the drug may fluctuate depending on factors such as the purchasing region, medical insurance policies, procurement channels and market conditions.
If you wish to learn about real-time prices, purchasing procedures or relevant preferential policies, please scan the QR code provided on the company official website to contact our professional customer service team directly for detailed consultation. We will provide you with one-on-one answers and service support.
1. Pralsetinib should be stored at room temperature, between 68°F and 77°F (20°C and 25°C). For short periods of time, such as during transportation, it can be exposed to temperatures ranging from 59°F to 86°F (15°C to 30°C).
2. Store the medication in a tightly sealed container at room temperature, away from heat sources, moisture and direct sunlight. Do not freeze.
3. Keep it out of the reach of children.
4. Do not retain expired or unused medications.
5. Consult your doctor about the proper disposal of any unused medication.
6. Overdose and Missed Dose of Pralsetinib
1. If you or someone else has taken an overdose of Pralsetinib, seek medical attention immediately.
2. What should I do if I miss a dose of Pralsetinib?
3. If you miss a dose, take the missed dose as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and take only the next scheduled dose. Do not take a double dose or an extra dose.
4. If you vomit after taking the medication, do not take an additional dose. Instead, take the next dose at the regular scheduled time.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended:[list:visits]2026-30-07
Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched(1) Quizartinib is an oral tablet.···【more】
Recommended:[list:visits]2026-29-07
Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vientiane, the capital ···【more】
Recommended:[list:visits]2026-28-07
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Dr···【more】
Recommended:[list:visits]2026-24-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended:[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended:[list:visits]2026-21-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643